Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering is viewed favorably because its lead drug atebimetinib uses Deep Cyclic Inhibition to deliver deep MAPK suppression while avoiding the chronic toxicity that has historically limited MEK inhibitors, giving it a plausible mutation-agnostic role across KRAS-driven tumors. The 55-patient pancreatic cancer cohort showed a 17.3-month median OS, 8.3-month median PFS, 36% ORR, 82% DCR, and 84% of patients maintained or gained weight, while safety stayed notably clean with only chemotherapy-related grade 3+ anemia and neutropenia above 10%. With about $199 million in cash and runway into 2029, Immuneering appears funded through the mid-2028 MAPKeeper 301 readout, where a randomized survival benefit could validate both atebimetinib and the broader DCI platform.

Immuneering is viewed negatively because its investment case depends on early-stage MEK biology that has repeatedly struggled in RAS-driven tumors, where prior inhibitors delivered modest response and PFS gains without improving overall survival and often increased serious adverse events. The company’s own thesis rests heavily on atebi’s Phase 3 1L PDAC outcome, yet Phase 2 evidence was single-arm, showed only 5% ORR and 52% DCR, and may have been confounded by patient-selection differences such as lower liver-metastasis rates versus historical controls. Financially, it had $198.6 million of cash at 31 March, but with operating losses, expected R&D expansion, and potential future equity financing, dilution risk and the need for capital remain significant.